2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Metabolic Syndrome
1
Lymphoma, Non-Hodgkin
1
Heart Failure
1
Dyslipidemias
1
Central Nervous System Neoplasms
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Cardiomyopathies
1
Interventions
Rituximab
344
Cyclophosphamide
317
fludarabine phosphate
142
Etoposide
139
Peripheral Blood Stem Cell Transplantation
124
fludarabine
112
Filgrastim
112
Mycophenolic Acid
98
Melphalan
98
Whole-Body Irradiation
90
Vincristine
90
Busulfan
87
Cytarabine
85
Doxorubicin
79
Cyclosporine
76
Tacrolimus
75
Radiotherapy
75
Prednisone
73
Bendamustine Hydrochloride
72
Granulocyte Colony-Stimulating Factor
66
Methotrexate
65
Antilymphocyte Serum
56
Carmustine
54
Dexamethasone
50
Gemcitabine
48
Lenalidomide
46
Bortezomib
43
venetoclax
41
ibritumomab tiuxetan
37
obinutuzumab
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
Pulse Wave Analysis
×
Clear all
NCT07041827
2025-06-27
CLARITY
The Netherlands Cancer Institute
Completed
217 enrolled